Results 111 to 120 of about 11,407 (210)

Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae [PDF]

, 2017
The spread of carbapenemase-producing Klebsiella pneumoniae is a major public health concern since such isolates are basically resistant to most available antibiotics, including β-lactams, fluoroquinolones and aminoglycosides.1 Infections due to ...
Dubois, Véronique, Jayol, Aurélie, Nordmann, Patrice, Poirel, Laurent   +3 more
core   +1 more source

Distribution and Drug‐Resistance Analysis of Uropathogens in Urinary Tract Infections

Canadian Journal of Infectious Diseases and Medical Microbiology, Volume 2026, Issue 1, 2026.
Background Urinary tract infections (UTIs) are a major global health concern with increasing antimicrobial resistance. Regional data on pathogen distribution and resistance patterns are essential for guiding empirical therapy. This study aimed to investigate the distribution and antimicrobial resistance profiles of UTI pathogens in Shanghai, China, and
Weiyi Wu, Qiong Wu, Wenying Zhong, Lizhong Han, Mohsin Khurshid   +4 more
wiley   +1 more source

Identification of a Novel KPC Variant, KPC-204, Conferring Resistance to Both Carbapenems and Ceftazidime–Avibactam in an ST11 Klebsiella pneumoniae Strain

Microorganisms
This study describes KPC-204, a novel variant of Klebsiella pneumoniae carbapenemase, characterized by a Lys-Asp-Asp (KDD) amino acid insertion at Ambler position 269 deviates from KPC-2.
Yanqiao Gong, Yu Feng, Xiaoju Lv
doaj   +1 more source

In vitro Synergistic Activity of Ceftazidime-Avibactam in Combination with Aztreonam or Meropenem Against Clinical Enterobacterales Producing blaKPC or blaNDM

Infection and Drug Resistance, 2023
Junyang Kuai,1 Yawei Zhang,1 Binghuai Lu,2 Hongbin Chen,1 Yulin Zhang,2 Henan Li,1 Yuanyuan Wang,3 Qi Wang,1 Hui Wang,1 Xiaojuan Wang1 1Department of Clinical Laboratory, Peking University People’s Hospital, Beijing, People’s Republic of China ...
Kuai J, Zhang Y, Lu B, Chen H, Zhang Y, Li H, Wang Y, Wang Q, Wang H, Wang X   +9 more
doaj  

Risk factors and outcomes for ineffective empiric treatment of sepsis caused by gram-negative pathogens: Stratification by onset of infection [PDF]

, 2017
Sepsis and septic shock remain serious consequences of infections, with reported mortality rates in excess of 40 percent. Timely antibiotic therapy in cases of sepsis and septic shock is recognized as an important determinant of outcome.
Hampton, Nicholas, Kollef, Marin, Micek, Scott T   +2 more
core   +2 more sources

Evolution of ceftazidime-avibactam and cefiderocol resistance in ST131-H30R1-Escherichia coli isolates with KPC-3 mutants and application of FTIR biotyping

Microbiology Spectrum
Ceftazidime-avibactam and cefiderocol represent two of the few alternatives for infections by KPC-producing Enterobacterales. We reported the emergence of resistance to both ceftazidime-avibactam and cefiderocol in a KPC-producing ST131-Escherichia coli (
Juan Antonio Castillo-Polo, Marta Hernández-García, Ainhize Maruri-Aransolo, Carmen de la Vega, Patricia Ruiz-Garbajosa, Rafael Cantón   +5 more
doaj   +1 more source

Molecular mechanisms responsible KPC-135-mediated resistance to ceftazidime-avibactam in ST11-K47 hypervirulent Klebsiella pneumoniae

Emerging Microbes and Infections
Ceftazidime-avibactam resistance attributable to the blaKPC-2 gene mutation is increasingly documented in clinical settings. In this study, we characterized the mechanisms leading to the development of ceftazidime-avibactam resistance in ST11-K47 ...
Qingyu Shi, Siquan Shen, Chengkang Tang, Li Ding, Yan Guo, Yang Yang, Shi Wu, Renru Han, Dandan Yin, Fupin Hu   +9 more
doaj   +1 more source

Effective antibiotic conservation by emergency antimicrobial stewardship during a drug shortage [PDF]

, 2016
We present the first description of an antimicrobial stewardship program (ASP) used to successfully manage a multi-antimicrobial drug shortage. Without resorting to formulary restriction, meropenem utilization decreased by 69% and piperacillin-tazobactam
Casabar, Ed, Durkin, Michael J, Hays, Amanda J, Hsueh, Kevin, Jafarzadeh, S. Reza, Krekel, Tamara, Lane, Michael A, Reyes, Maria, Ritchie, David J   +8 more
core   +2 more sources

Ceftazidime/Avibactam: Who Says You Can’t Teach an Old Drug New Tricks?

Journal of Pharmacy & Pharmaceutical Sciences, 2016
Purpose: Gram-negative resistance continues to rise with treatment options becoming more limited. Ceftazidime/avibactam was recently approved in the United States and Europe, which combines an established third-generation cephalosporin with a new, unique,
Katie E. Barber, Jessica K. Ortwine, Ronda L Akins   +2 more
doaj   +1 more source

Tackling carbapenem resistance: ceftazidime - avibactam in contemporary clinical scenarios

International Journal of Advances in Medicine
Antimicrobial resistance poses a formidable challenge in treating severe infections, with the prevalence of extended-spectrum beta-lactamase (ESBL) - producing, Klebsiella pneumoniae carbapenemase (KPC) - producing, and multidrug-resistant (MDR) organisms on the rise.
Manish Maladkar, Shrikant Patil, Namita Anchan   +2 more
openaire   +1 more source